EMITF-M Stock Overview
Develops, produces, and markets therapeutic medical systems for performing non-invasive treatments on the human body in Israel and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 2/6 |
Elbit Imaging Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₪5.20 |
| 52 Week High | ₪5.25 |
| 52 Week Low | ₪3.30 |
| Beta | 0.59 |
| 11 Month Change | 7.22% |
| 3 Month Change | 38.59% |
| 1 Year Change | 18.18% |
| 33 Year Change | -10.42% |
| 5 Year Change | 112.59% |
| Change since IPO | -99.37% |
Recent News & Updates
Shareholder Returns
| EMITF-M | IL Medical Equipment | IL Market | |
|---|---|---|---|
| 7D | 5.3% | -10.6% | 1.7% |
| 1Y | 18.2% | 6.3% | 28.0% |
Return vs Industry: EMITF-M exceeded the IL Medical Equipment industry which returned 6.3% over the past year.
Return vs Market: EMITF-M underperformed the IL Market which returned 28% over the past year.
Price Volatility
| EMITF-M volatility | |
|---|---|
| EMITF-M Average Weekly Movement | 5.5% |
| Medical Equipment Industry Average Movement | 6.0% |
| Market Average Movement | 3.9% |
| 10% most volatile stocks in IL Market | 7.4% |
| 10% least volatile stocks in IL Market | 2.8% |
Stable Share Price: EMITF-M's share price has been volatile over the past 3 months compared to the IL market.
Volatility Over Time: EMITF-M's weekly volatility (6%) has been stable over the past year, but is still higher than 75% of IL stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | n/a | Ron Hadassi | n/a |
Elbit Imaging Ltd., together with its subsidiaries, develops, produces, and markets therapeutic medical systems for performing non-invasive treatments on the human body in Israel and internationally. The company offers treatment-oriented medical systems with ultrasound beam and magnetic resonance imaging for noninvasive treatments in human body. It also offers medical products based on stem cells derived primarily from umbilical cord blood and intended for bone marrow transplantation in patients with leukemia or lymph node cancer, non-malignant blood diseases, and metabolic genetic diseases.
Elbit Imaging Ltd. Fundamentals Summary
| EMITF-M fundamental statistics | |
|---|---|
| Market cap | ₪55.33m |
| Earnings (TTM) | -₪678.00k |
| Revenue (TTM) | ₪328.00k |
168.7x
P/S Ratio-81.6x
P/E RatioIs EMITF-M overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EMITF-M income statement (TTM) | |
|---|---|
| Revenue | ₪328.00k |
| Cost of Revenue | ₪0 |
| Gross Profit | ₪328.00k |
| Other Expenses | ₪1.01m |
| Earnings | -₪678.00k |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.064 |
| Gross Margin | 100.00% |
| Net Profit Margin | -206.71% |
| Debt/Equity Ratio | 0% |
How did EMITF-M perform over the long term?
See historical performance and comparison